XBiotech Inc. — Q1 2020 Form 10-Q
Reporting period: Three months ended March 31, 2020. XBiotech is a pre-commercial biopharmaceutical company developing naturally occurring “True Human” monoclonal antibodies. The period’s first reported revenue came from agreements with Janssen following the December 2019 transaction.
Financial performance and position
| Metric | Q1 2020 | Q1 2019 / comparison |
|---|---|---|
| Revenue | $12.681 million | $0 |
| Cost of goods sold | $9.674 million | $0 |
| Gross profit / margin | $3.007 million / approximately 23.7% | Not applicable |
| Operating expenses | $5.178 million | $5.805 million |
| Operating loss | $2.171 million | $5.805 million |
| Net loss | $14,000; basic and diluted loss per share rounded to $0.00 | $5.864 million; $0.16 per share |
| Operating cash flow | $(60.673) million | $(4.677) million |
| Cash and cash equivalents | $241.540 million at March 31 | $714.594 million at December 31, 2019 |
| Current assets / current liabilities | $257.896 million / $10.235 million | $716.263 million / $60.190 million at December 31, 2019 |
Cash used in investing activities was $0.389 million. Financing activities used $412.082 million, principally the $420 million share repurchase, partly offset by $7.918 million from option exercises. The company reported total liabilities of $11.291 million; no borrowings or debt are identified in the supplied filing text. The balance sheet includes a $75 million escrow receivable, which the company says it expects to receive in 2021.
Material changes and drivers
- Janssen-related manufacturing revenue was $3.0 million and clinical-trial services revenue was $9.681 million. Clinical-trial services revenue included pass-through costs and a 30% markup; the associated costs were recorded in cost of goods sold.
- Research and development expense fell 74% to $1.155 million, mainly because manufacturing and clinical-trial department costs associated with the Janssen agreements were classified as cost of goods sold rather than R&D.
- General and administrative expense rose 215% to $4.023 million, primarily due to $2.144 million in share-based compensation and higher professional fees, including tender-offer costs.
- Interest income increased to $1.898 million from $78,000. The company recorded a $352,000 income tax benefit in Q1 2020.
- In February, XBiotech repurchased 14 million shares at $30 per share for approximately $420 million, about 32.67% of shares outstanding. Shares outstanding at March 31 were 28.853 million, compared with 41.520 million at December 31.
Outlook, risks, and unusual items
- COVID-19 caused syringe supply disruptions that prevented completion of part of a Janssen manufacturing order; $1.5 million was deferred until the relevant volumes are completed and delivered. Janssen also requested delays in shipments and reduced its manufacturing order. XBiotech received syringes in April and expected to return to normal manufacturing capacity by Q3 2020, subject to pandemic-related uncertainty.
- The company said Q1 results may not indicate future Janssen revenue or costs. It warned that supply constraints, reduced orders, clinical-trial delays, remote-work and staffing issues, and regulatory or financing disruption could adversely affect operations and liquidity.
- Management expected Janssen revenues to support R&D activities over the next two years and stated cash was expected to be sufficient through one year from the report’s issuance. The filing also cautions that additional financing may be needed and that profitability may never be achieved.
- After quarter-end, XBiotech announced a BioBridge Global collaboration related to an FDA investigational convalescent-plasma program and said a novel anti-IL-1 alpha antibody had advanced as a product candidate, with a planned return to clinical trials in 2021. These were announcements, not reported Q1 revenue.
- Management reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.
Key facts for investors to verify
- Confirm the timing and collection of the $75 million escrow receivable and the expected Janssen contract receipts, including the effect of any further order reductions or termination rights.
- Track whether manufacturing capacity returned to normal by Q3 2020 and whether deferred manufacturing revenue was subsequently recognized.
- Reconcile cash runway and operating cash use, particularly the large tax payment and the impact of future clinical, manufacturing, and COVID-19-related spending.
- Review source figures carefully: the statements report a Q1 net loss of $14,000, while MD&A elsewhere describes net losses of $0.3 million; the clinical-services revenue is generally reported as $9.681 million, though one note describes a different amount. The supplied filing text does not resolve these inconsistencies.